APEL DANIEL JOSEPH (Chief Financial Officer) sold 7.4% of their position (13.10K shares) of ARROWHEAD PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $934.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/24/2026ACC: 0000879407-26-000039
Officer· Chief Financial Officer
Since Apr 2025
-13.10K
Net shares
Net seller
$934.3K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
13.10K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−3.21K
Price / share
$70.11
Trade value
$224.91K
% of position
1.8%
4/22/2026
176K→172.79K
Common Stock
Direct
Shares
−1.16K
Price / share
$70.45
Trade value
$81.51K
% of position
0.7%
4/22/2026
172.79K→171.63K
Common Stock
Direct
Shares
−8.73K
Price / share
$71.92
Trade value
$627.86K
% of position
5.1%
4/22/2026
171.63K→162.91K
Total
Net shares
−13.10K
Net value
-$934.29K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/22/2026 | S · Sale | −3.21K | $70.11 | $224.91K | 1.8% | 176K | 172.79K |
| Common Stock Direct | 4/22/2026 | S · Sale | −1.16K | $70.45 | $81.51K | 0.7% | 172.79K | 171.63K |
| Common Stock Direct | 4/22/2026 | S · Sale | −8.73K | $71.92 | $627.86K | 5.1% | 171.63K | 162.91K |
| Total | −13.10K | -$934.29K | ||||||
Derivative Transactions0
No derivative transactions reported